QuidelOrtho Corp. 10-Q Summary: Q1 2026
Business Context and Reporting Period
This filing is a Quarterly Report (Form 10-Q) for QuidelOrtho Corporation for the three-month period ended March 29, 2026. The company operates globally in the diagnostics sector, reporting across five geographic segments: North America, EMEA, China, JPAC, and Latin America. The company is a large accelerated filer with 68.2 million shares of common stock outstanding as of the period end.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenues | $619.8 million | $692.8 million |
| Net Loss | $(91.8) million | $(12.7) million |
| Operating Loss | $(31.8) million | $32.6 million (Income) |
| Adjusted EBITDA (Total Segments) | $242.3 million | $309.7 million |
| Cash and Cash Equivalents | $140.4 million | $127.2 million |
| Net Cash Used in Operating Activities | $(33.0) million | $65.6 million (Provided) |
| Total Debt (Current + Long-term) | $2,688.0 million | $2,650.2 million |
| Cost of Sales Margin | 57.4% | 50.4% |
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased 11% year-over-year. This was driven by a 34% drop in Point of Care revenue (due to lower SARS antigen assay sales) and a 39% drop in Donor Screening revenue (due to the wind-down of the U.S. portfolio). The termination of the Joint Business arrangement with Grifols also contributed to a $13.3 million revenue decrease.
- Profitability Deterioration: The company swung from an operating income of $32.6 million in Q1 2025 to an operating loss of $31.8 million in Q1 2026. Net loss widened significantly to $91.8 million.
- Cash Flow Reversal: Operating cash flow turned negative, using $33.0 million compared to generating $65.6 million in the prior year. This was primarily due to the net loss and a $72.6 million cash outflow for inventory buildup, partially offset by $54.0 million in receivable collections.
- Expense Trends: Cost of sales as a percentage of revenue increased to 57.4% from 50.4%, driven by higher employee compensation. Restructuring charges decreased to $4.4 million from $16.1 million in the prior year.
Outlook, Risks, and Unusual Items
- Strategic Initiatives: The company is executing the "Optimization Plan" targeting $100 million in cumulative pre-tax charges through 2027 to achieve $50 million in net cost savings. Additionally, the company is exiting the SAVANNA molecular diagnostics platform, expected to be complete by mid-2027.
- Acquisition: On April 17, 2026 (subsequent event), the company acquired LEX Diagnostics for approximately $100 million in cash to expand its molecular diagnostics portfolio.
- Market Risks:
- Respiratory Seasonality: Demand for influenza products was lower due to a weaker respiratory season (30% fewer flu-like illness visits vs. prior year).
- China Pricing: Uncertainty regarding new IVD pricing guidelines from the China National Health Security Administration contributed to slower distributor sales in the China segment.
- Geopolitics: Ongoing conflicts in the Middle East caused delays in EMEA orders. New U.S. tariffs and trade tensions are increasing supply chain costs.
- Legal Proceedings: The company faces a putative class action lawsuit regarding COVID-19 test sales and the SAVANNA assay, as well as derivative complaints. The company disputes the allegations and cannot estimate potential losses.
Investor Verification Checklist
- Respiratory Demand: Verify the severity and duration of the current flu/RSV season and its impact on Q2 and Q3 revenue guidance.
- China Regulatory Impact: Monitor the finalization of China's IVD pricing guidelines to assess the long-term impact on the Labs segment.
- Optimization Plan Execution: Track the realization of the targeted $50 million in cost savings against the $100 million in restructuring charges.
- Liquidity Position: Review the company's ability to service $2.69 billion in debt while operating cash flow is negative and capital expenditures continue.
- LEX Diagnostics Integration: Assess the timeline for integrating LEX Diagnostics and the potential for revenue accretion in the molecular diagnostics segment.